By Russell Clark, FNP-C, APRN · Based on The 30-Week Tirzepatide Reset · May 11, 2026
A dual-acting medication targeting both GLP-1 and GIP receptors, providing a more comprehensive metabolic signal than single-hormone treatments.
The definitive guide by Russell Clark, FNP-C, APRN